RADIANCE Study Group. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomized, placebo-controlled, phase 2 trial.
Academic Article
Publication Date:
2016
Iris type:
1.1 Articolo in rivista
List of contributors:
Cohen, Ja; Arnold, Dl; Comi, Giancarlo; Bar Or, A; Gujrathi, S; Hartung, Hp; Cravets, M; Olson, A; Frohna, Pa; Selmaj, Kw
Published in: